AstraZeneca: IDMC Recommends Primary Analysis For OlympiA Phase III Trial

(RTTNews) – AstraZeneca PLC (AZN.L, AZN) said the OlympiA phase III trial for AstraZeneca and MSD’s Lynparza will move to early primary analysis and reporting following a recommendation from the Independent Data Monitoring Committee. Based on the planned interim analysis, the IDMRead MoreMarketsMarkets Feed